US 12,410,132 B2
Antiplatelet drugs and uses thereof
Zi-Qiang Gu, Reston, VA (US); Yuanchao Zhang, Fulton, MD (US); Gongxin He, Shanghai (CN); Kai Hou, Shanghai (CN); and Hao Wu, Shanghai (CN)
Assigned to SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD., Shanghai (CN)
Appl. No. 18/018,576
Filed by SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD., Shanghai (CN)
PCT Filed Jul. 28, 2021, PCT No. PCT/CN2021/108875
§ 371(c)(1), (2) Date Jan. 29, 2023,
PCT Pub. No. WO2022/022559, PCT Pub. Date Feb. 3, 2022.
Claims priority of application No. PCT/CN2020/105513 (WO), filed on Jul. 29, 2020.
Prior Publication US 2024/0279178 A1, Aug. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 211/72 (2006.01); A61K 31/445 (2006.01); A61K 31/4525 (2006.01); A61P 7/02 (2006.01); C07D 401/12 (2006.01)
CPC C07D 211/72 (2013.01) [A61K 31/445 (2013.01); A61K 31/4525 (2013.01); A61P 7/02 (2018.01); C07D 401/12 (2013.01)] 14 Claims
 
1. A compound having Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein

OG Complex Work Unit Chemistry
 represents a double bond in Z or E configuration;
R1 is selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl is optionally substituted with one or more Ra;
R2 is —C(O)Rb;
R3 is selected from hydrogen or alkyl;
L is alkyl;
W is selected from:

OG Complex Work Unit Chemistry
wherein the * end of W is connected to L;
R4 is selected from hydrogen or alkyl;
each of Ra is independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, cyano, nitro, or —NRcRd,
Rb is —ORe;
each of Rc and Rd is independently selected from hydrogen or alkyl;
Rc is alkyl;
n is 0, 1 or 2.